Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-MART-1 F5 TCR tumor infiltrating lymphocytes

A preparation of human tumor infiltrating lymphocytes (TILs) isolated from a melanoma patient and engineered to encode a T-cell receptor (TCR) specific for an epitope of MART-1 (F5 TCR), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MART-1 F5 TCR TILs may recognize and halt the growth of MART-1-expressing melanoma cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-MART-1 F5 TCR gene-engineered TILs autologous anti-MART-1 F5 TCR gene-engineered tumor infiltrating lymphocytes autologous anti-MART-1 F5 TCR TILs autologous anti-MART-1 F5 TCR-engineered TILs

autologous anti-MART-1 F5 TCR tumor infiltrating lymphocytes

Search NCI's Drug Dictionary